Le Lézard
Classified in: Health
Subjects: MAV, CFG

/R E M I N D E R -- Media Advisory - Deputy Prime Minister's itinerary for Saturday, March 30, 2024/


Note: All times local.

TORONTO, March 29, 2024 /CNW/ -

1:00 p.m.

The Deputy Prime Minister will make a health care announcement in advance of the 2024 federal budget. The Minister of Mental Health and Addictions and Associate Minister of Health, Ya'ara Saks, will also be in attendance. A media availability will follow.




Notes for media:



?  Media wishing to cover the event are asked to arrive no later than 12:30 p.m.



?  Media must register by contacting [email protected].

This document is also available at https://deputypm.canada.ca/en

SOURCE Deputy Prime Minister's Office


These press releases may also interest you

at 17:00
Zepp Health Corporation Announces Receipt of NYSE Non-compliance Letter Regarding ADS Trading Price
Zepp Health Corporation ("Zepp" or the "Company") , a global leader in smart wearables and health technology, today announced that it has received a letter from the New York Stock Exchange (the "NYSE") dated April 30, 2024, notifying Zepp that it is...

at 16:55
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
Revelation Biosciences, Inc. (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March...

at 16:55
Maple Counseling Announces Pioneering Partnership with Saban Community Clinic to Expand Access to Mental Health Services
Maple Counseling has partnered with Saban Community Clinic to launch the Saban Partnership Program, aimed at enhancing access to mental healthcare for underserved communities. This initiative includes the introduction of four bilingual Associate...

at 16:35
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
Bristol Myers Squibb today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). CheckMate -73L evaluated...

at 16:35
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...

at 16:35
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a...

More news about Health...


News published on and distributed by: